(4 Dec 2017) The dengvaxia vaccination is not recommended for people who have no previous infection of dengue fever, the manufacturer of the vaccine said on Monday.
Officials from pharmaceutical company Sanofi Pasteur made the announcement at a news conference in Manila on Monday.
Dr. Ng Su Peing, Global Medical Head of Sanofi Pasteur gave the recommendation after the Philippines Department of Health put its dengue immunisation programme on hold.
The move comes after new findings by the French drug company that showed severe cases of dengue can occur in the longer term among those vaccinated with Dengvaxia without prior dengue infection.
Philippines health officials put the vaccination programme on hold pending a recommendation expected mid-December by the Strategic Advisory Group of Experts (SAGE) on immunisation, an advisory body of the World Health Organisation.
More than 730,000 public school children aged 9 and above in three highly endemic Philippine regions have received at least the first dose of Dengvaxia, the first licensed dengue vaccine.
The Department of Health launched the 3.5 billion peso (69.5 million US dollar) programmelast year.
Find out more about AP Archive: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
You can license this story through AP Archive: [ Ссылка ]
